AQR Capital Management’s Cytosorbents Corp CTSO Stock Holding History

AQR Capital Management’s Portfolio CTSO Stock Details CTSO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-40,437	Closed	-$169K	–	2230
2021 Q4	$169K	Buy	40,437 +23,024	+132%	+$129K	﹤0.01%	2109
2021 Q3	$141K	Sell	17,413 -67,514	-79%	-$548K	﹤0.01%	2184
2021 Q2	$641K	Sell	84,927 -35,859	-30%	-$302K	﹤0.01%	1797
2021 Q1	$1.05M	Sell	120,786 -1,638	-1%	-$15.6K	﹤0.01%	1530
2020 Q4	$976K	Sell	122,424 -6,618	-5%	-$55.4K	﹤0.01%	1515
2020 Q3	$1.03M	Buy	+129,042	New	+$1.16M	﹤0.01%	1395
2019 Q4	–	Sell	-15,501	Closed	-$78K	–	2128
2019 Q3	$78K	Sell	15,501 -11,057	-42%	-$64.3K	﹤0.01%	2094
2019 Q2	$176K	Sell	26,558 -6,179	-19%	-$42.4K	﹤0.01%	1992
2019 Q1	$248K	Hold	32,737	–	–	﹤0.01%	2028
2018 Q4	$265K	Hold	32,737	–	–	﹤0.01%	1998
2018 Q3	$422K	Hold	32,737	–	–	﹤0.01%	2004
2018 Q2	$373K	Buy	+32,737	New	+$310K	﹤0.01%	2068
2015 Q3	–	Sell	-24,706	Closed	-$152K	–	2182
2015 Q2	$152K	Buy	+24,706	New	+$168K	﹤0.01%	2136

Other funds holding CTSO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return

Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

AQR Capital Management's CTSO Position: Q1 2022 in Review

AQR Capital Management sold out of Cytosorbents Corp (CTSO) in Q1 2022, closing a stake of 40,437 shares — an estimated $169K sold.

AQR Capital Management first reported a position in CTSO in Q2 2015 and held it in 13 quarters. The position peaked at $1.05M in Q1 2021. 88 funds tracked by Wall St. Rank hold CTSO as of Q1 2022.

AQR Capital Management reported no remaining Cytosorbents Corp position as of Q1 2022 after selling out during the quarter.
AQR Capital Management sold 40,437 Cytosorbents Corp shares in Q1 2022, an estimated $169K.
AQR Capital Management first reported a position in Cytosorbents Corp in Q2 2015 and held it in 13 quarters.
AQR Capital Management's Cytosorbents Corp position peaked at $1.05M in Q1 2021.
88 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2022.

Based on AQR Capital Management's 13F filing for Q1 2022, filed 16 May 2022.